西黄胶囊联合CIK细胞治疗晚期鼻咽癌临床研究  

Clinical study on Xihuang capsule combined with CIK cells in the treatment of advanced nasopharyngeal carcinoma

作　　者：任庆 熊锐华 何玉婵 诸葛金科 陆东兰 蒋小月 REN Qing;XIONG Ruihua;HE Yuchan;ZHUGE Jinke;LU Donglan;JIANG Xiaoyue(The Second Affiliated Hospital of Guilin Medical College,Guilin 541199,Guangxi,China)

机构地区：[1]桂林医学院第二附属医院,广西桂林541199

出　　处：《现代中西医结合杂志》2021年第6期584-587,592,共5页Modern Journal of Integrated Traditional Chinese and Western Medicine

基　　金：2016年广西中医药民族医药传承创新专项课题(GZLC16-48)。

摘　　要：目的探讨西黄胶囊联合细胞因子诱导的杀伤细胞(CIK)治疗晚期鼻咽癌的临床疗效。方法选择桂林医学院第二附属医院2016年1—12月收治的60例晚期鼻咽癌患者,随机分为观察组和对照组,观察组给予西黄胶囊联合CIK细胞治疗,对照组给予吉西他滨联合顺铂方案化疗,治疗4个周期。观察2组近期疗效,比较2组患者治疗前后外周血中T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))分布、NK细胞(CD16^(+)CD56^(+))水平及生活质量,记录2组不良反应发生情况、中位无进展生存时间(PFS)和2年生存率。结果观察组患者治疗后客观缓解率为6.7%(2/30),CD3^(+)、CD4^(+)、CD8^(+)、CD16^(+)、CD56^(+)均较治疗前明显升高(P均<0.05),PFS为6.6个月,2年生存率为86.7%(26/30);对照组患者治疗后客观缓解率为40.0%(12/30),淋巴细胞亚群指标均较治疗前明显降低(P均<0.05),PFS为6.8个月,2年生存率为93.3%(28/30)。2组PFS和2年生存率比较差异均无统计学意义(P均>0.05)。治疗后对照组心理健康及生理健康评分较治疗前无明显变化甚至有下降趋势(P均>0.05),观察组各指标评分则明显升高且明显高于对照组(P均<0.05)。观察组治疗期间出现恶心呕吐1例,经对症处理后缓解;对照组发生恶心呕吐11例,骨髓抑制7例,腹泻3例,皮疹2例。结论西黄胶囊联合CIK细胞治疗晚期鼻咽癌较常规西医化疗可明显提高患者的细胞免疫功能,改善生活质量,且无明显不良反应。Objective It is to explore the clinical efficacy of Xihuang capsule combined with cytokine-induced killer cells(CIK)in the treatment of advanced nasopharyngeal carcinoma.Methods Sixty patients with advanced nasopharyngeal carcinoma admitted to the Second Affiliated Hospital of Guilin Medical College from January to December 2016 were randomly divided into observation group and control group.The observation group was treated with Xihuang capsule combined with CIK cell,and the control group was treated with gemcitabine combined cisplatin regimen chemotherapy,both groups were treated for 4 cycles.The short-term efficacy of the two groups was observed,the distribution of T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+)),NK cell(CD16^(+)CD56^(+))levels in the peripheral blood and quality of life of patients of the two groups were compared before and after treatment,and the occurrence of adverse reactions,progression-free survival time(PFS)and 2-year survival rate were recorded in the two groups.Results The objective remission rate of patients in the observation group after treatment was 6.7%(2/30),and CD3^(+),CD4^(+),CD8^(+),CD16^(+),CD56^(+)were significantly higher than those before treatment(all P<0.05),PFS was 6.6 months,the 2-year survival rate was 86.7%(26/30);the objective remission rate of patients in the control group after treatment was 40.0%(12/30),and the lymphocyte subset indicators were significantly lower than those before treatment(P all<0.05),PFS was 6.8 months,and the 2-year survival rate was 93.3%(28/30).There was no significant difference in PFS and 2-year survival rate between the two groups(P>0.05).After treatment,the mental health and physical health scores of the control group did not change significantly or even declined compared with those before the treatment(all P>0.05),and the scores of each index in the observation group increased significantly and were significantly higher than those of the control group(all P<0.05).One case of nausea and vomiting occurred in the observation group during tre

关 键 词：西黄胶囊 细胞因子诱导的杀伤细胞 晚期 鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]